Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nabriva Therapeutics Plc (NBRV)

Nabriva Therapeutics Plc (NBRV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Nabriva Therapeutics Plc 25-28 NORTH WALL QUAY IFSC DUBLIN L2 19406 IRL

www.nabriva.com P: 353-1649-2000

Description:

Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP).

Key Statistics

Overview:

Market Capitalization, $K 45,461
Enterprise Value, $K 38,141
Shares Outstanding, K 32,015
Annual Sales, $ 36,940 K
Annual Net Income, $ -57,190 K
Last Quarter Sales, $ 7,590 K
Last Quarter Net Income, $ -8,700 K
60-Month Beta 1.53
% of Insider Shareholders 1.63%
% of Institutional Shareholders 0.27%
Float, K 31,493
% Float 98.37%
Short Volume Ratio 0.53

Growth:

1-Year Return -68.34%
3-Year Return -99.23%
5-Year Return -99.79%
5-Year Revenue Growth 594.36%
5-Year Earnings Growth 96.58%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.72 on 05/22/23
Latest Earnings Date 08/02/23
Earnings Per Share ttm -19.20
EPS Growth vs. Prev Qtr 64.99%
EPS Growth vs. Prev Year 45.60%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 09/16/22

NBRV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -365.53%
Return-on-Assets % -135.81%
Profit Margin % -154.82%
Debt/Equity -0.08
Price/Sales 1.23
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.14
Interest Coverage -78.46
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar